Guidant Surveys Resynch Pool: Doc Loyalty, Sales Presence Will Rule The Day
This article was originally published in The Gray Sheet
Executive Summary
Cardiac resynchronization defibrillator procedures, by their inherent complexity, will foster loyalty to a single manufacturer's CRT-D devices, Guidant President and CEO Ron Dollens asserted at JPMorgan's annual healthcare conference in San Francisco Jan. 12
You may also be interested in...
“V-to-V” Pacing Impact On CRT-D Market May Be Minimal, Physician Claims
An effective sales force can successfully compete with incremental or unproven technology advances in cardiac rhythm management, according to electrophysiologist Bradford Sodowick, MD, St. Mary Medical Center, Langhorne, Penn
“V-to-V” Pacing Impact On CRT-D Market May Be Minimal, Physician Claims
An effective sales force can successfully compete with incremental or unproven technology advances in cardiac rhythm management, according to electrophysiologist Bradford Sodowick, MD, St. Mary Medical Center, Langhorne, Penn
Guidant fights for patent rights
St. Jude Medical's Atlas+ HF and Epic HF defibrillators and Frontier pacemaker infringe its RE38,119 E "Mower" patent, Guidant alleges in a suit filed in Wilmington, Del. federal court Feb. 2. Atlas and Epic are expected to be approved by FDA in May (1"The Gray Sheet" Jan. 10, 2004, p. 8). According to a filing by St. Jude with the Securities & Exchange Commission, "the '119 patent is also the subject of a lawsuit between Guidant and Medtronic in the same court." St. Jude intends to "vigorously" defend the allegation...